Association between adherence to calcium-channel blocker and statin medications and likelihood of cardiovascular events among US managed care enrollees

Table 3 Logistic regression model of medication adherence (PDC ≥80%) at 6 months following initiation of SPAA or CCB+statin

		95% Confidence Limits
	Odds Ratio	Lower	Upper	Chi-Square	p-value
Drug Group: SPAA vs. CCB+Statin	4.70	4.22	5.23	793.06	<.001
Gender: Female vs. Male	1.21	1.13	1.30	30.59	<.001
Pre-index Comorbidity of:
Diabetes Mellitus	1.00	0.92	1.07	0.02	0.891
Dyslipidemia	1.22	1.14	1.32	27.80	<.001
Obesity	0.84	0.72	0.98	5.15	0.023
Peripheral Vascular Disease	0.75	0.59	0.94	6.26	0.012
Chronic Obstructive Pulmonary Disease	0.82	0.67	0.99	4.17	0.041
Number of Pre-Index Other Antihypertensive Classes	1.12	1.06	1.18	18.93	<.001

ISSN: 1471-2261